Price T Rowe Associates Inc. MD Sells 2,121,474 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

Price T Rowe Associates Inc. MD cut its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 98.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,597 shares of the biopharmaceutical company’s stock after selling 2,121,474 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Regulus Therapeutics were worth $47,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in RGLS. JPMorgan Chase & Co. increased its holdings in shares of Regulus Therapeutics by 141.2% during the fourth quarter. JPMorgan Chase & Co. now owns 190,457 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 111,485 shares during the period. Barclays PLC increased its holdings in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares during the period. PEAK6 LLC bought a new position in shares of Regulus Therapeutics during the fourth quarter worth approximately $95,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Regulus Therapeutics by 20.5% during the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 19,900 shares during the period. 92.38% of the stock is owned by institutional investors.

Regulus Therapeutics Stock Performance

NASDAQ RGLS opened at $7.87 on Monday. The firm’s fifty day moving average price is $3.41 and its two-hundred day moving average price is $2.10. The stock has a market cap of $544.87 million, a PE ratio of -7.36 and a beta of 0.49. Regulus Therapeutics Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $8.20.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14. As a group, sell-side analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on RGLS shares. Leerink Partners reissued a “market perform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. StockNews.com started coverage on shares of Regulus Therapeutics in a research note on Sunday. They issued a “sell” rating on the stock. Wells Fargo & Company reissued an “equal weight” rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a research note on Thursday, May 1st. Jones Trading reissued a “hold” rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Friday, March 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.50.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.